CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)

CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)

This study explores the therapeutic potential of targeting CXCR2 in patients afflicted with ponatinib-resistant chronic myeloid leukemia (CML). Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), was initially designed for treating patients with CML harboring the T315I mutation. However,...

Full description

Bibliographic Details
Main Authors: Ji-Hea Kim, Ka-Won Kang, Yong Park, Byung Soo Kim
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Heliyon
Subjects:
Ponatinib-resistant CML
CXCR2
IL-8
GRO-A
Tyrosine kinase inhibitors
Leukemic stem cells
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402309299X

Internet

http://www.sciencedirect.com/science/article/pii/S240584402309299X

Similar Items